// App-Quantinova.ai

5013 : Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Johann S. De Bono

Principal Investigators

  • Lawrence Fong

  • Tomasz M. Beer

  • Xin Gao

  • Daniel M. Geynisman

  • Howard A. Burris III

  • James Fredric Strauss

  • Kevin Dale Courtney

  • David I. Quinn

  • Yifah Yaron

  • Che-Leung Law

  • Mark N. Stein

  • David James Vander

  • Weele

Medical Centers

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Dana-Farber Cancer Institute, Boston, MA

  • Fox Chase Cancer Center, Department of Hematology and Oncology, Philadelphia, PA

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Texas Oncology, Dallas, TX

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Norris Cancer Hospital, Los Angeles, CA

  • The University of Chicago Medical Center, Chicago, IL

  • CytomX Therapeutics, South San Francisco, CA

  • Columbia University Medical Center, New York, NY

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • lipase

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT03577028

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved